Company
Psyence Group, Inc.
Headquarters: Toronto, ON, Canada
Psyence Group, Inc. Categories
Canada Healthcare Drug Manufacturers—GeneralCanada Healthcare Canada Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
| AbbVie | $285.06 B |
| Roche | $240.44 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities in Canada and internationally. Its natural psilocybin is used for the long-term treatment of psychological trauma and its mental health consequences. The company also engages in developing therapeutic, hallucinogenic and subhallucinogenic dosing, and treatment protocols for the treatment of anxiety, depression, PTSD, grief, and bereavement. In addition, it focuses on the development of over-the-counter IP protected nutraceutical products for mental wellbeing. The company has a collaboration agreement with Scientific Research Council of Jamaica for psilocybin product development. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Psyence Group, Inc. has the following listings and related stock indices.
Stock: CSE: PSYG wb_incandescent